UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C.  20549



FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934



For the month of March 2007



Commission File Number: 001-31368



SANOFI-AVENTIS

(Translation of registrants name into English)



174, avenue de France, 75013 Paris, FRANCE

(Address of principal executive offices)



Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.


|Form 20-Fx | Form 40-Fo
|---------- | ----------

|Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): _____
|---------------------------------------------------------------------------------------------------------------------------------

|Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): _____
|---------------------------------------------------------------------------------------------------------------------------------

|Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

|Yeso | Nox
|---- | ---

|If Yes marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82-________
|-------------------------------------------------------------------------------------------------------------------------












---



In March 2007, sanofi-aventis issued the press releases attached hereto as Exhibit 99.1, 99.2 and 99.3 which are incorporated herein by reference.



Exhibit List



Exhibit No.
        DescriptionExhibit 99.1
        Press release dated March 26, 2007 Rimonabant USA: UpdateExhibit 99.2
        Press release dated March 22, 2007 Acomplia® (rimonabant) is now officially reimbursable in France, for the treatment of eligible obese and Type 2 diabetic patientsExhibit 99.3
        Press release dated March 16, 2007 LANTUS®SoloSTAR® and APIDRA®SoloSTAR® New Disposable Insulin Pensfor People with Type 1 and Type 2 Diabetes Will Be Launched Starting April 2007 in Europe














2






---



SIGNATURES



Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.



Dated: March 26, 2007
        SANOFI-AVENTISBy:
      /s/ Patricia KodyraName:
      Patricia KodyraTitle:
      Associate Vice President
      Financial and Securities Law




















3






---



Exhibit Index



Exhibit No.
        DescriptionExhibit 99.1
        Press release dated March 26, 2007 Rimonabant USA: UpdateExhibit 99.2
        Press release dated March 22, 2007 Acomplia® (rimonabant) is now officially reimbursable in France, for the treatment of eligible obese and Type 2 diabetic patientsExhibit 99.3
        Press release dated March 16, 2007 LANTUS®SoloSTAR® and APIDRA®SoloSTAR® New Disposable Insulin Pensfor People with Type 1 and Type 2 Diabetes Will Be Launched Starting April 2007 in Europe
























4